ABBV

SEC source: 0001415889-25-012793 · form4-05132025_050503.xml · nonDerivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,646

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012794 · form4-05132025_050505.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,458

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012795 · form4-05132025_050507.xml · nonDerivative · entry 1

BURNSIDE WILLIAM H.L. · CIK 0001563579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,958

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012796 · form4-05132025_050509.xml · nonDerivative · entry 1

Davis Jennifer L. · CIK 0001916665 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,525

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012797 · form4-05132025_050511.xml · nonDerivative · entry 1

Hart Brett J · CIK 0001466338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,472

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012798 · form4-05132025_050513.xml · nonDerivative · entry 1

MEYER MELODY B · CIK 0001706126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,498

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012799 · form4-05132025_050515.xml · nonDerivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,525

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012800 · form4-05132025_050518.xml · nonDerivative · entry 1

Roberts Rebecca B · CIK 0001355580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,728

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012801 · form4-05132025_050520.xml · nonDerivative · entry 1

WADDELL FREDERICK H · CIK 0001223690 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,958

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012802 · form4-05132025_050522.xml · nonDerivative · entry 1

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,751

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012803 · form4-05132025_050524.xml · nonDerivative · entry 1

TILTON GLENN F · CIK 0001194624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,564

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-012804 · form4-05132025_050526.xml · nonDerivative · entry 1

FALK THOMAS J · CIK 0001222890 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,203

F1 · balance_after: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-25-009687 · form4-04022025_050401.xml · derivative · entry 5

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,700 shares

Expires 2029-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

F4 · derivative.exercise_date: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-009687 · form4-04022025_050401.xml · nonDerivative · entry 3

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,234

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.54 to $210.63, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-009687 · form4-04022025_050401.xml · nonDerivative · entry 2

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,366

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.43 to $209.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-009687 · form4-04022025_050401.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-009688 · form4-04022025_050404.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 386,479

SEC source: 0001415889-25-009689 · form4-04022025_050407.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 476

Underlying: Common Stock · 71 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-009690 · form4-04022025_050409.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,361

Underlying: Common Stock · 155 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-009691 · form4-04022025_050412.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,907

Underlying: Common Stock · 35 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-25-008437 · form4-03182025_050302.xml · nonDerivative · entry 1

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,577

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.27 to $212.49, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · derivative · entry 11

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,549

Underlying: Common Stock · 7,775 shares

Expires 2034-02-14

F4 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · derivative · entry 10

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,314

Underlying: Common Stock · 7,315 shares

Expires 2033-02-15

F4 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · derivative · entry 9

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,918 shares

Expires 2032-02-16

F4 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 8

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,619

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 7

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,627

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 6

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,852

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 5

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,537

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006579 · form4-03042025_050304.xml · nonDerivative · entry 3

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 388,929

SEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 4

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,130

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.3 to $211.4, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 3

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,730

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.25 to $211.23, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 2

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,703

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.16 to $210, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 4

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,619

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.12 to $207.37, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 3

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,982

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.01 to $207, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,793

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.99 to $205.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006578 · form4-03042025_050301.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,511

SEC source: 0001415889-25-006579 · form4-03042025_050304.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 395,097

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.09 to $205.45, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006579 · form4-03042025_050304.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 487,557

SEC source: 0001415889-25-006580 · form4-03042025_050307.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,380

SEC source: 0001415889-25-006581 · form4-03042025_050309.xml · nonDerivative · entry 1

SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, CHIEF OPERATIONS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,292

SEC source: 0001415889-25-006582 · form4-03042025_050312.xml · nonDerivative · entry 1

Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,366

SEC source: 0001415889-25-006583 · form4-03042025_050314.xml · nonDerivative · entry 1

Michael Robert A. · CIK 0001699914 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,821

SEC source: 0001415889-25-006584 · form4-03042025_050316.xml · nonDerivative · entry 1

Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,221

SEC source: 0001415889-25-006585 · form4-03042025_050318.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,018

SEC source: 0001415889-25-006586 · form4-03042025_050321.xml · nonDerivative · entry 1

Buckbee Kevin K · CIK 0001968528 · SVP, CONTROLLER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,797

SEC source: 0001415889-25-006587 · form4-03042025_050323.xml · nonDerivative · entry 1

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,276

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · derivative · entry 8

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,210 shares

Expires 2028-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 7

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,284

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024.

F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.55 to $203.68, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 6

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,113

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024.

F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.55 to $203.46, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-25-006024 · form4-02282025_050201.xml · nonDerivative · entry 5

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,186

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024.

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.55 to $202.48, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.